Patient Evaluation and Follow-up
To reduce patient burden, timing of data collection was scheduled according to the choice of chemotherapy regimen, where patients who received temozolomide were assessed every 4 weeks, while patients treated with lomustine or PCV where assessed every 6 weeks. All patients in the study were assigned to undergo MRI and clinical examination at 3-month intervals as part of study protocol. Compliance of disulfiram and copper was assessed by tablet count at the study visits, in addition to patient self-reporting. Patient-reported health-related quality of life (HRQoL) was measured with EuroQol-5D-3L (EQ-5D),